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Abstract
© 2018 Chulpanova, Kitaeva, Tazetdinova, James, Rizvanov and Solovyeva. Mesenchymal stem
cells (MSCs) are non-hematopoietic progenitor cells, which can be isolated from different types
of tissues including bone marrow, adipose tissue, tooth pulp, and placenta/umbilical cord blood.
There isolation from adult tissues circumvents the ethical concerns of working with embryonic or
fetal stem cells, whilst still providing cells capable of differentiating into various cell lineages,
such as adipocytes, osteocytes and chondrocytes. An important feature of MSCs is the low
immunogenicity due to the lack of co-stimulatory molecules expression, meaning there is no
need for immunosuppression during allogenic transplantation. The tropism of MSCs to damaged
tissues and tumor sites makes them a promising vector for therapeutic agent delivery to tumors
and metastatic niches. MSCs can be genetically modified by virus vectors to encode tumor
suppressor  genes,  immunomodulating  cytokines  and  their  combinations,  other  therapeutic
approaches include MSCs priming/loading with chemotherapeutic drugs or nanoparticles. MSCs
derived  membrane  microvesicles  (MVs),  which  play  an  important  role  in  intercellular
communication,  are also considered as a new therapeutic agent and drug delivery vector.
Recruited by the tumor,  MSCs can exhibit  both pro-  and anti-oncogenic properties.  In this
regard,  for  the  development  of  new  methods  for  cancer  therapy  using  MSCs,  a  deeper
understanding  of  the  molecular  and  cellular  interactions  between  MSCs  and  the  tumor
microenvironment  is  necessary.  In  this  review,  we  discuss  MSC  and  tumor  interaction
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